Thursday, March 26, 2020
LifeScius, Inc. is a therapeutics seed phase startup at the VA BIO+ TECH Park, focused on the discovery and development of novel drugs to treat unmet medical needs of the central nervous system and oncology.
The company was founded in 2019 by Dr. Eliseu De Oliveira, a medicinal chemist experienced in small molecule drug discovery and development (Georgetown, VCU). LifeScius develops its proprietary drug portfolio in partnership with industry, research institutes, and universities, covering activities from the discovery phase up to FDA Phase-2 clinical trials. As its key strategy, LifeScius researches new medical applications of drugs already on the market with a long history of safety and efficacy. More than just repurposing these drugs, the company investigates what mechanisms of action explain their novel activity, and then designs and tests proprietary chemical structures to engage new biological targets. This approach significantly shortens the time of discovery and development from decades to a couple of years, which both mitigates the risk of drug failure and optimizes the return over investments.
Currently, LifeScius is developing a novel procognitive drug candidate based on its lead molecule LS1001, derived from the structure of a generic antipsychotic drug with clinical evidence of cognitive activity through the engagement of the 5-HT7 serotonin receptors. The company aims for a drug that normalizes cognitive function in patients affected by brain neurodegenerative disorders and trauma, with application to the treatment of traumatic brain injury (TBI), cognitive impairments of schizophrenia (CIS), post-stroke psychosis (PSP), and Alzheimer's disease (AD), among others. The company is applying for a Phase 1 NIH SBIR grant to expand its initial discovery and pre-clinical research activities to establish its proof of concept.
For more information, please contact Dr. De Oliveira at email@example.com.